论文部分内容阅读
目的通过观察恩替卡韦治疗慢性乙型肝炎对肝脏组织病理和肝纤维化指标的影响,评估其抗肝纤维化的疗效.方法选取慢性乙型肝炎患者81例,随机分为两组,治疗组41例,恩替卡韦0.5 mg,1次/d,口服;对照组40例,给予常规护肝药物治疗,疗程均为48周.观察治疗后肝纤维化指标和肝活组织病理改变,并进行比较.结果治疗后两组患者肝纤维化指标均明显下降,治疗组比对照组下降更为显著,肝组织学评估结果有显著改善(P<0.05).结论恩替卡韦治疗慢性乙型肝炎肝纤维化临床疗效确切,无严重不良反应.
Objective To observe the effects of entecavir on liver histopathology and liver fibrosis indicators in patients with chronic hepatitis B and evaluate its anti-hepatic fibrosis effect.Methods 81 patients with chronic hepatitis B were randomly divided into two groups, 41 cases in the treatment group , Entecavir 0.5 mg once a day orally; control group of 40 patients given conventional liver protection drug treatment for 48 weeks.Observed liver fibrosis indicators and liver biopsy pathological changes, and compared.Results Treatment The indexes of liver fibrosis in the latter two groups were significantly decreased, the treatment group decreased more significantly than the control group, and the result of liver histological evaluation was significantly improved (P <0.05) .Conclusion Efficacy of entecavir in the treatment of chronic hepatitis B liver fibrosis has definite curative effect, No serious adverse reactions.